Discover and read the best of Twitter Threads about #inhibitors
Most recents (2)
With passage of the National Alzheimer’s Project Act (NAPA) in January 2011 and the subsequent “National Plan to Address Alzheimer’s Disease”, the war on Alzheimer’s has only just begun. But one key aspect is glaringly absent: specific funding commitments
science.org/doi/10.1126/sc…
science.org/doi/10.1126/sc…
More than 5 million Americans now suffer from Alzheimer, and that number is expected to more than double by 2050. Between 1998-2011, there were 101 unsuccessful AD drugs in development and only three approvals (none since 2003)
@AndrewWLo Kenneth @KosikLab
science.org/doi/10.1126/sc…
@AndrewWLo Kenneth @KosikLab
science.org/doi/10.1126/sc…
"If a single drug-development program takes 13 years
from beginning to end and has a 5% probability of success, the expected waiting time for the next approved Alzheimer's disease drug is 260 years"
-@AndrewWLo, Carole Ho, Jayna Cummings, @kennethskosik
from beginning to end and has a 5% probability of success, the expected waiting time for the next approved Alzheimer's disease drug is 260 years"
-@AndrewWLo, Carole Ho, Jayna Cummings, @kennethskosik
The Road to Paxlovid (PF-07321332)
A thread. #paxlovid #protease #inhibitors #ivermectin #COVID19
Dr. John Campbell: Paxlovid vs Ivermectin
A thread. #paxlovid #protease #inhibitors #ivermectin #COVID19
Dr. John Campbell: Paxlovid vs Ivermectin
New Pfizer antiviral and ivermectin, a pharmacodynamic analysis. Paxlovid (PF-07321332), C₂₃H₃₂F₃N₅O₄
Paxlovid is designed to block the activity of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate. Co-administration with a low dose of
Paxlovid is designed to block the activity of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate. Co-administration with a low dose of
ritonavir helps slow the metabolism, or breakdown, of Paxlovid in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus. Paxlovid inhibits viral replication at a stage known as proteolysis, which occurs before
